Amino acid glutamine important for eye health, finds study

The retina places a large energy demand on the body, in part due to the activity of photoreceptors.

These specialized cells are responsible for receiving light and transmitting visual information to the brain.

Photoreceptor death is the cause of vision loss in many retinal diseases, and there are no effective therapies that improve their survival.

In a paper published in eLife, University of Michigan researchers studied the dependence of photoreceptors on glutamine.

Their results indicate that maintaining the balance of amino acids in these cells is important for photoreceptor health.

The energy requirements of photoreceptors make them vulnerable to small changes in metabolism.

Previous studies focused on glucose as the primary fuel source for these cells.

Currently, therapy that exploits photoreceptor dependence on glucose is being tested in a clinical trial for patients with retinal degeneration.

“Photoreceptors are one of the most metabolically demanding cells in the body, which led us to wonder whether they depend on fuel sources other than glucose for their survival,” said Thomas Wubben, M.D., Ph.D., assistant professor of ophthalmology and visual sciences.

“We looked at glutamine because it is the most abundant amino acid in the blood.”

Glutamine feeds into several pathways, helping cells build other amino acids, including glutamate and aspartate, protein and DNA.

To confirm glutamine’s role in vision, the researchers used mice that lacked the enzyme glutaminase, which breaks down glutamine into glutamate.

They compared these mice to control mice by measuring the thickness of their retinas.

Mice that lacked glutaminase had a rapid reduction in retinal thickness with loss of photoreceptor number and function.

Glutamine plays a role in several cellular processes.

To understand why glutamine is important to photoreceptor survival, the team measured the levels of different molecules in control mice and those that lacked glutaminase.

When mice lacked the enzyme, they had lower levels of glutamate and aspartate.

These amino acids, in turn, help the cells build proteins that are required for photoreceptor function.

The researchers also found that decreased amino acid levels activated the integrated stress response, which is known to trigger cell death if it remains active for too long.

When they inhibited the stress response, the team found that the retinal thickness increased.

“We are now focused on understanding which pathways depend on glutamine and whether they can be targeted by drugs or supplements,” Wubben said.

Glutamine to glutamate conversion pathways are negatively impacted in models of human retinal disease.

“It is possible that resetting metabolism can help prevent vision loss and blindness.”

Reference:

Moloy T GoswamiEric WehShubha SubramanyaKatherine M WehHima Bindu DurumutlaHeather HagerNicholas MillerSraboni ChaudhuryAnthony AndrenPeter SajjakulnukitLi ZhangCagri BesirliCostas A LyssiotisThomas J Wubben (2025) Glutamine catabolism supports amino acid biosynthesis and suppresses the integrated stress response to promote photoreceptor survival eLife 13:RP100747. https://doi.org/10.7554/eLife.100747.3

Powered by WPeMatico

The Parity Factor: Understanding Its Role in Gestational Diabetes, finds study

Recent investigation assessed the relationship between parity and gestational diabetes mellitus (GDM) occurrence while considering additional influencing factors among a large cohort of Chinese women. The prevalence of GDM has significantly increased, particularly in China, driven by rising rates of obesity, advanced maternal age, and changing reproductive policies. GDM, associated with numerous adverse outcomes for both mothers and infants, necessitates a clearer understanding of its risk factors.

Understanding Parity’s Role

Parity, defined as the number of times a woman has given birth, has been inconsistently associated with GDM in existing literature. Some studies suggest that higher parity may reduce the risk due to physiological changes that enhance insulin sensitivity, while others indicate that it may increase risk. This study aimed to elucidate the independent effect of parity on GDM risk while adjusting for confounders including maternal age and pre-pregnancy body mass index (BMI), both recognized as significant GDM predictors.

Data Analysis and Findings

Data from 198,237 participants, collected via the Shenzhen Maternal and Child Health Information Management System, revealed significant variations in GDM prevalence with parity. The prevalence was higher among multiparous women compared to nulliparous, particularly in the 30-45 age group. Logistic regression models indicated that multiparae had a lower risk of GDM than primiparae, confirmed after controlling for age, education, ethnicity, and pre-pregnancy BMI. Notably, the interaction between maternal age and parity indicated that the protective effect of multiparity was more pronounced in women aged 20-29 years compared to older groups.

Possible Mechanisms Behind GDM Risk

Further analysis suggested that several psychosocial and physiological mechanisms might contribute to the observed decreased GDM risk in multiparous women. Multiparae generally possess greater prenatal awareness and adherence to health guidelines gained from previous pregnancies, potentially leading to better dietary and health management, reducing GDM risk. Moreover, higher physical activity levels due to socioeconomic conditions and social support among multiparous women may further mitigate stress and enhance pregnancy outcomes. Despite the robustness of the study, limitations included the reliance on clinical records for GDM diagnosis which may introduce bias and the single-center nature of the study affecting generalizability. The findings indicate the essentiality of addressing parity in GDM risk assessments, especially highlighting the need for targeted counseling in nulliparous women of advanced maternal age, aiming to effectively reduce GDM incidence through informed reproductive planning. Further research is warranted to explore the underlying mechanisms influencing parity and GDM risk.

Key Points

– -Prevalence and Context-: The study highlights a significant increase in the prevalence of gestational diabetes mellitus (GDM) in China, attributed to rising obesity rates, advanced maternal age, and shifting reproductive policies, underscoring the necessity for a deeper understanding of GDM risk factors.

– -Parity’s Inconsistent Association-: Parity’s relationship with GDM has been inconsistent in existing literature, with some studies suggesting higher parity might lower GDM risk due to enhanced insulin sensitivity, while others indicate it could increase risk. This investigation aimed to clarify the independent effects of parity on GDM, adjusting for confounding variables like maternal age and pre-pregnancy BMI.

– -Cohort Data and Findings-: An analysis of 198,237 participants from the Shenzhen Maternal and Child Health Information Management System demonstrated that multiparous women had a higher prevalence of GDM compared to nulliparous women, particularly within the 30-45 age bracket. Logistic regression showed that multiparae had a lower risk of GDM than primiparae once accounting for confounders.

– -Impact of Maternal Age on Parity-: The interaction between maternal age and parity revealed that the protective effect of multiparity against GDM risk was more significant in younger women (ages 20-29) than in older demographics, suggesting that age modulates the influence of parity on GDM risk.

– -Psychosocial and Physiological Mechanisms-: Analysis indicated potential psychosocial and physiological mechanisms contributing to reduced GDM risk in multiparous women, such as enhanced prenatal awareness and adherence to health guidelines from previous pregnancies, along with increased physical activity and social support.

– -Study Limitations and Implications-: Acknowledged limitations include reliance on clinical records for GDM diagnosis, which could introduce bias, and the study’s single-center approach affecting generalizability. Findings emphasize the importance of incorporating parity in GDM risk assessments, advocating for targeted counseling for nulliparous women of advanced maternal age to mitigate GDM incidence and support informed reproductive planning. Further research is needed to investigate the mechanisms governing the relationship between parity and GDM risk.

Reference –

Yuqin Dai et al. (2025). Impact Of Parity On Gestational Diabetes Mellitus In Chinese Women: A Retrospective Cohort Study. *BMC Pregnancy And Childbirth*, 25. https://doi.org/10.1186/s12884-025-07620-1.

Powered by WPeMatico

Breaking a sweat: Using chloride in sweat to help diagnose cystic fibrosis

Sweat does more than just cool down an overheating body. Measuring the chemical makeup of an individual’s sweat-specifically the levels of chloride, a chemical component of salt-can serve as an early warning system to help inform the diagnosis of cystic fibrosis, a genetic disease that damages the lungs and digestive system.

A group of researchers at Penn State recently developed a wearable device capable of accurately tracking chloride ion levels in sweat, which is essential for evaluating hydration status and health conditions like cystic fibrosis and more. Their sensor allows for real-time tracking of an exercising person’s sweat through a hydrogel-based design that allows the device to operate with enhanced sensitivity, accuracy and efficiency, all while being reusable. Their research, available online, is set to publish in the November issue of Biosensors and Bioelectronics.

“The traditional method of measuring chloride ion levels is to go to a hospital and have the measurements taken, which is time consuming and expensive,” said Wanqing Zhang, a doctoral candidate in engineering science and mechanics and co-author of the paper. “The wearable sensors we developed process sweat and track chloride ion levels in real time, directly on a subject’s body. This gives researchers a lot of information about an individual’s health and, specifically for this study, can identify the high chloride ion levels that signify the presence of cystic fibrosis.”

Wearable sensor technology is not new, with several other devices-including those that detect specific biomarkers in sweat-originating just from research at Penn State. However, Zhang explained how different existing designs face different major issues. Colorimetric based sweat sensors, which change color depending on the presence of a specific chemical or reaction, cannot produce reversible readings. If the sensor detects high chloride ion levels, it cannot revert to a neutral state and measure low levels, meaning that researchers can only take one accurate reading before needing to apply a new sensor. Another design, known as a potentiometric sweat sensor, operates by measuring the potential energy difference between two electrodes. While these sensors offer continuous monitoring, they typically have a limited sensitivity and rely on expensive ion-selective membranes to function.

According to Zhang, the research team’s new sensor uses multiple types of hydrogel — a water-rich, gel-like material made of networks of connected molecules called polymers — to address these issues simultaneously.

The team’s sensor contains a sweat chamber, a cation-selective hydrogel (CH) with mobile cations and a high salinity hydrogel (HH) with high salt content like sweat. When sweat enters the chamber, the difference in salt concentration between the sweat and the HH causes the mobile cations in the CH to move from the HH side to the sweat chamber side, generating open-circuit voltage (OCV) between the two points. By tracking this voltage — which indicates how many chloride ions are present in the sweat sample — they can track the levels of chloride ions.

“In other sensor designs, it is extremely difficult or impossible to effectively track small fluctuations in the chloride ion levels,” said Huanyu “Larry” Cheng, the James L. Henderson, Jr. Memorial Associate Professor of Engineering Science and Mechanics and corresponding author on the paper. “By incorporating two different types of hydrogel into the design of our sensor, we can measure the change in OCV across the sensor in real time, meaning we can follow the fluctuation of chloride ion levels in our subject’s sweat.”

However, using just these hydrogel solutions posed some issues, Zhang explained. Hydrogel material is a network of hydrophilic polymers, or materials highly attracted to water, meaning that water and electrolytes could easily pierce into the gels. The team used a material, known as PVDF-HFP film, to isolate their hydrogels from excess water or electrolytes that could negatively impact the sensor’s accuracy.

“This was the primary challenge we faced during development — when we were using just the two types of the hydrogel, water would cause the gel to swell, degrading performance,” Zhang said. “By using the PVDF-HFP film like a barrier between the hydrogel, we were able to protect the hydrogel from excess water, so it could effectively stabilize and facilitate OCV.”

To test the sensor, the team conducted two different experiments. They first collected sweat from a subject exercising and analyzed it using the sensor separately from the subject’s body. They then monitored the sweat as the subject wore the sensor while exercising, tracking chloride ion levels in a software that graphs information in real time. The readings of both experiments were then compared to confirm the accuracy of the sensor’s readings.

The sensor collects data very quickly, measuring and visualizing chloride ion levels in under 10 seconds. According to Zhang, the sensor is significantly more sensitive than existing sensors, producing readings with an accuracy of 174 millivolts per decade – nearly triple the theoretical limit of 59.2 millivolts per decade seen in potentiometric sensors. In addition to excellent reversibility, Zhang explained how the sensor’s high consistency and independence from past readings ensures easy, accurate readouts without having to make connections between multiple past readings, improving reusability.

While their sensor was primarily designed to help identify chloride ion levels indicative of cystic fibrosis, Cheng said he believes the design is a strong foundation for future wearable devices that could sense other biomarkers.

“This sensor has opened the door for low-cost, scalable and wearable chloride sensors,” Cheng said. “We believe that the mechanics used in our design can be adapted to reversibly monitor other ions or chemical compounds that appear in sweat, like glucose, which would provide additional insight on a subject’s health. The mechanics could also be expanded to different applications and platforms beyond just wearable devices, which we are exploring now.” 

Reference:

Wanqing Zhang, Xianzhe Zhang, Ankan Dutta, Farnaz Lorestani, Md Abu Sayeed Biswas, Bowen Li, Abu Musa Abdullah, Huanyu Cheng, Hydrogel-based sweat chloride sensor with high sensitivity and low hysteresis, Biosensors and Bioelectronics, https://doi.org/10.1016/j.bios.2025.117805.

Powered by WPeMatico

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients: Study

For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic variants that can impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting chemotherapy can significantly improve patient safety by providing physicians with information to help tailor doses, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Those who were found to have one of the genes had half as many side effects in half, as compared to patients with the genes that were given standard doses without testing, according to results published today in JCO Precision Oncology.

“For too long, the U.S. lagged behind Europe in adopting genetic testing for chemotherapy dosing, but our study shows it’s not only feasible but also critical for patient safety,” said the study’s lead author, Sony Tuteja, PharmD, MS, Director of Pharmacogenomics in the Penn Medicine Center for Genomic Medine, a research assistant professor of Translational Medicine and Human Genetics. “With up to 1,300 deaths in the U.S. each year due to side effects from one of the most common forms of chemotherapy drugs, we’ve worked to make testing fast and actionable, getting results in about a week to help doctors make safer treatment decisions.”

Nearly 290,000 Americans are diagnosed with gastrointestinal cancers each year – including colorectal cancer, the third most common cancer diagnosis in the nation. Current chemotherapy protocols use standard dosing standards that don’t account for genetic differences in how patients process these drugs.

Genetic Variants Guide Safer Chemotherapy

The study focused on variants in two genes: DPYD and UGT1A1. The DPYD gene produces an enzyme that helps the liver break down drugs like fluoropyrimidines, which are commonly used in gastrointestinal cancer treatment. About 5 to 8% of people carry DPYD variants that hinder the body’s ability to process fluoropyrimidine chemotherapy drugs, causing them to build up to harmful levels, which can lead to serious side effects like reduced blood cell production, mouth sores, or hand-foot syndrome. Similarly, the UGT1A1 gene affects how the body processes irinotecan, another key chemotherapy drug often used to treat GI cancers. Variants in UGT1A1 can lead to the body processing the drug too slowly, increasing the risk of severe diarrhea or low white blood cell counts. By identifying these variants, doctors can lower chemotherapy doses to prevent harmful side effects without compromising treatment effectiveness.

The study enrolled 517 GI cancer patients at three cancer care sites in the University of Pennsylvania Health System who were scheduled to begin chemotherapy treatment with fluoropyrimidine or irinotecan. A group of 288 received blood tests to check for DPYD and UGT1A1 variants. Among 16 patients who were found to have genetic variants and received tailored dose reductions based on test results, 38% experienced severe treatment-related adverse events. In comparison, 65% of 17 patients with the genetic variants from a biobank group who received standard doses without prior testing experienced the serious side effects. The tested group also saw a significantly lower need to change treatment dosage and frequency (38% vs. 76%) and fewer treatment discontinuations (31% vs. 47%), highlighting the potential of precision medicine to enhance patient safety and outcomes.   

Powered by WPeMatico

Drugs and Cosmetics Act Set for Fresh Decriminalization Under Jan Vishwas Bill 2025

New Delhi: The Drugs and Cosmetics Act, 1940, key legislation governing India’s pharmaceutical sector, is set for further decriminalization under the Jan Vishwas (Amendment of Provisions) Bill, 2025, introduced in the Lok Sabha by Union Commerce and Industry Minister Piyush Goyal.

Alongside the pharma law, the bill also proposes amendments to the Tea Act, 1953, Legal Metrology Act, 2009, and Motor Vehicles Act, 1988, marking the next phase of the government’s sweeping regulatory reform agenda.

Union Commerce and Industry Minister Piyush Goyal has introduced the Jan Vishwas (Amendment of Provisions) Bill, 2025, in the Lok Sabha. The bill, which was earlier cleared by the Union Cabinet, has been referred to the Select Committee by the Hon’ble Speaker for detailed examination, with a report expected by the first day of the next session.

This exercise builds on the success of the Jan Vishwas (Amendment of Provisions) Act, 2023—the first consolidated legislation to systematically decriminalize minor offenses across multiple acts. The 2023 Act, notified on 11th August 2023, decriminalized 183 provisions in 42 Central Acts administered by 19 Ministries/Departments.

Notably, the Drugs and Cosmetics Act, 1940, which was part of the 2023 reforms, is among the four acts—along with the Tea Act, 1953, Legal Metrology Act, 2009, and Motor Vehicles Act, 1988—proposed for further decriminalization under the current bill.

The 2025 Bill expands this reform agenda to cover 16 Central Acts administered by 10 Ministries/Departments. A total of 355 provisions are proposed to be amended—288 provisions decriminalized to foster ease of doing business, and 67 provisions proposed to be amended to facilitate ease of living.

The Jan Vishwas (Amendment of Provisions) Bill, 2025, also proposes 67 amendments under the New Delhi Municipal Council Act, 1994 (NDMC Act) and the Motor Vehicles Act, 1988, to facilitate ease of living.

Key features of the bill:

First-time contraventions: Advisory or warning for 76 offenses under 10 acts.

Decriminalization: Imprisonment clauses for minor, technical or procedural defaults are replaced with monetary penalties or warnings.

Rationalization of penalties: Penalties made proportionate, with graduated penalties for repeated offenses.

Adjudication mechanisms: Designated officers empowered to impose penalties through administrative processes, reducing judicial burden.

Revision of fines and penalties: Automatic 10% increase every three years to maintain deterrence without legislative amendments.

Four acts—the Tea Act, 1953; the Legal Metrology Act, 2009; the Motor Vehicles Act, 1988; and the Drugs and Cosmetics Act, 1940—were part of the Jan Vishwas Act, 2023 and are proposed for further decriminalization under the current bill.

The Jan Vishwas (Amendment of Provisions) Bill, 2025, marks a significant milestone in India’s regulatory reform journey. It reflects the government’s commitment to “Minimum Government, Maximum Governance” and will catalyze sustainable economic growth and improved ease of doing business.

Powered by WPeMatico

AI model simultaneously detects multiple genetic colorectal cancer markers in tissue samples

A multicenter study has analyzed nearly 2,000 digitized tissue slides from colon cancer patients across seven independent cohorts in Europe and the US. The samples included both whole-slide images of tissue samples and clinical, demographic, and lifestyle data.

Powered by WPeMatico

Glass half empty? Nutrition studies shouldn’t just focus on what parents do wrong

If it takes a village to raise a child, it also takes a village to care for children’s food needs.

Powered by WPeMatico

Companies may be misleading parents with ‘outrageous’ claims about banking baby teeth

Parents are spending thousands of pounds to bank stem cells from their children’s milk teeth—but the recipient companies’ claims about their future medical value are unproven and potentially misleading, reveals an investigation by The BMJ.

Powered by WPeMatico

Menopause misinformation is harming care, warn experts

Many direct to consumer menopause services are unnecessary and do not improve care, warn experts in The BMJ.

Powered by WPeMatico

Pilot study provides foundation for understanding how music therapy improves pain after pancreatic surgery

A study from University Hospitals Connor Whole Health has found that it was feasible to conduct a live music-assisted relaxation and imagery session among patients admitted for pancreatic surgery. Participants described the music therapy intervention as beneficial and useful throughout recovery while also providing feedback to improve the intervention and data collection procedures moving forward.

Powered by WPeMatico